PADI2 and glioblastoma: The PAD isozyme-specific inhibitors affected cell invasiveness differently in the two GBM cell lines and were overall more effective in reducing invasiveness in LN18 cells, with PAD2 inhibitor being most effective but overall all three PAD inhibitors showing significantly reduced invasion of LN18 cells, while in LN229 cells only PAD3 inhibitor significantly reduced invasion following 16 h treatment.